Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Ambarus, Carmen A ^a,b   Noordenbos, Troy ^a,b   de Hair, Maria J H ^a   Tak, Paul P ^a,c   Baeten, Dominique L P ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD32 ANTIGEN; INTERLEUKIN 10; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTIMA; INTIMA LINING LAYER MACROPHAGE; MACROPHAGE; MALE; MONOCYTE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYNOVITIS; SYNOVIUM; SYNOVIUM SUBLINING MACROPHAGE; AGED; BIOSYNTHESIS; CELL CULTURE; CHRONIC DISEASE; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELLS, CULTURED; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-10; MACROPHAGES; MALE; MIDDLE AGED; PHENOTYPE; SYNOVIAL MEMBRANE; SYNOVITIS; TUNICA INTIMA;

EID: 84859512024     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3796     Document Type: Article

References (62)

1. Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, Kraan M, Coleman M, Ahern MJ. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis 2003, 62:303-307. 10.1136/ard.62.4.303, 1754505, 12634226.
2. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217-225. 10.1002/art.1780400206, 9041933.
3. De Rycke L, Baeten D, Foell D, Kruithof E, Veys EM, Roth J, De KF. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005, 206:17-27. 10.1002/path.1758, 15809977.
4. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000, 43:2619-2633. 10.1002/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V, 11145019.
5. Baeten D, Kruithof E, De RL, Boots AM, Mielants H, Veys EM, De KF. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369. 10.1186/ar1501, 1065336, 15743484.
6. Baeten D, Houbiers J, Kruithof E, Vandooren B, Van den Bosch F, Boots AM, Veys EM, Miltenburg AM, De KF. Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis 2006, 65:990-997. 10.1136/ard.2005.047852, 1798244, 16414969.
7. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004, 50:3783-3791. 10.1002/art.20664, 15593225.
8. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:834-838. 10.1136/ard.2004.029751, 1755544, 15576415.
9. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007, 56:3869-3871. 10.1002/art.22964, 17968928.
10. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van DN, Cuvelier C, De VM, Mielants H, Veys EM, De KF. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001, 44:186-195. 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B, 11212159.
11. Canete JD, Celis R, Hernandez V, Pablos JL, Sanmarti R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2010, 69:935-936. 10.1136/ard.2009.113233, 19700394.
12. Kruithof E, De RL, Roth J, Mielants H, Van den Bosch F, De KF, Veys EM, Baeten D. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies. Arthritis Rheum 2005, 52:3898-3909. 10.1002/art.21426, 16329106.
13. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De KF. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005, 64:529-536. 10.1136/ard.2003.018549, 1755461, 15388510.
14. van Lent PL, Holthuysen AE, Van RN, Van De Putte LB, van den Berg WB. Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis. Ann Rheum Dis 1998, 57:408-413. 10.1136/ard.57.7.408, 1752671, 9797567.
15. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737. 10.1038/nri3073, 21997792.
16. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009, 60:1210-1221. 10.1002/art.24505, 19404968.
17. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292. 10.1084/jem.176.1.287, 2119288, 1613462.
18. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35. 10.1038/nri978, 12511873.
19. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686. 10.1016/j.it.2004.09.015, 15530839.
20. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969. 10.1038/nri2448, 2724991, 19029990.
21. Ambarus CA, Krausz S, van EM, Hamann J, Radstake TR, Reedquist KA, Tak PP, Baeten DL. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 2012, 375:196-206. 10.1016/j.jim.2011.10.013, 22075274.
22. Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van DN, De VM, Veys EM, De KF. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002, 196:343-350. 10.1002/path.1044, 11857499.
23. Baeten D, Moller HJ, Delanghe J, Veys EM, Moestrup SK, De KF. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004, 50:1611-1623. 10.1002/art.20174, 15146432.
24. Kruithof E, Baeten D, De RL, Vandooren B, Foell D, Roth J, Canete JD, Boots AM, Veys EM, De KF. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580. 10.1186/ar1698, 1174942, 15899044.
25. Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Canete JD, Baeten D. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012, 64:99-109. 10.1002/art.33396, 21968742.
26. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000, 67:97-103.
27. Vandooren B, Noordenbos T, Ambarus C, Krausz S, Cantaert T, Yeremenko N, Boumans M, Lutter R, Tak PP, Baeten D. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009, 60:966-975. 10.1002/art.24406, 19333931.
28. Smith JA, Barnes MD, Hong D, DeLay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum 2008, 58:1640-1649. 10.1002/art.23512, 2888278, 18512784.
29. van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis 2011, 70:423-427. 10.1136/ard.2010.139550, 21109518.
30. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227. 10.1002/art.1780341003, 1930310.
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
32. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D'Cruz D, Casanova JL, Trouillet C, Geissmann F. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33:375-386. 10.1016/j.immuni.2010.08.012, 3063338, 20832340.
33. Balsa A, Dixey J, Sansom DM, Maddison PJ, Hall ND. Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Br J Rheumatol 1996, 35:33-37. 10.1093/rheumatology/35.1.33, 8624620.
34. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002, 168:3536-3542.
35. Geissmann F, Auffray C, Palframan R, Wirrig C, Ciocca A, Campisi L, Narni-Mancinelli E, Lauvau G. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol 2008, 86:398-408. 10.1038/icb.2008.19, 18392044.
36. Serbina NV, Cherny M, Shi C, Bleau SA, Collins NH, Young JW, Pamer EG. Distinct responses of human monocyte subsets to Aspergillus fumigatus conidia. J Immunol 2009, 183:2678-2687. 10.4049/jimmunol.0803398, 2753882, 19635902.
37. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007, 81:584-592.
38. Blom AB, Radstake TR, Holthuysen AE, Sloetjes AW, Pesman GJ, Sweep FG, van de Loo FA, Joosten LA, Barrera P, van Lent PL, van den Berg WB. Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase. Arthritis Rheum 2003, 48:1002-1014. 10.1002/art.10871, 12687542.
39. Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, Ueno A, Ohmoto Y, Makino H. CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002, 46:2578-2586. 10.1002/art.10545, 12384915.
40. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 2012, 64(3):671-7. 10.1002/art.33418, 22006178.
41. Cairns AP, Crockard AD, Bell AL. The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 2002, 21:189-192.
42. Fleischer J, Soeth E, Reiling N, Grage-Griebenow E, Flad HD, Ernst M. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology 1996, 89:592-598. 10.1046/j.1365-2567.1996.d01-785.x, 1456589, 9014827.
43. Sanchez C, Domenech N, Vazquez J, Alonso F, Ezquerra A, Dominguez J. The porcine 2A10 antigen is homologous to human CD163 and related to macrophage differentiation. J Immunol 1999, 162:5230-5237.
44. Bourlier V, Zakaroff-Girard A, Miranville A, De BS, Maumus M, Sengenes C, Galitzky J, Lafontan M, Karpe F, Frayn KN, Bouloumie A. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 2008, 117:806-815. 10.1161/CIRCULATIONAHA.107.724096, 18227385.
45. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obesity (Lond) 2007, 31:1420-1428.
46. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011, 41:2522-2525. 10.1002/eji.201141894, 21952810.
47. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011, 6:275-297. 10.1146/annurev-pathol-011110-130138, 21034223.
48. Wilson HM. Macrophages heterogeneity in atherosclerosis: implications for therapy. J Cell Mol Med 2010, 14:2055-2065. 10.1111/j.1582-4934.2010.01121.x, 20629993.
49. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010, 24:241-255. 10.1101/gad.1874010, 2811826, 20080943.
50. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan LJ, Hammond R, Gimotty PA, Keith B, Simon MC. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 2010, 120:2699-2714. 10.1172/JCI39506, 2912179, 20644254.
51. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555. 10.1016/S1471-4906(02)02302-5, 12401408.
52. Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 2008, 205:1673-1685. 10.1084/jem.20072602, 2442644, 18559453.
53. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885. 10.1056/NEJMoa0905680, 2897174, 20220182.
54. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 2009, 125:367-373. 10.1002/ijc.24401, 19378341.
55. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184. 10.1172/JCI29881, 1716210, 17200717.
56. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red EA, Vats D, Brombacher F, Ferrante AW, Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120. 10.1038/nature05894, 2587297, 17515919.
57. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 2010, 299:E1016-E1027. 10.1152/ajpendo.00329.2010, 3006260, 20841504.
58. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002, 8:1235-1242. 10.1038/nm1102-1235, 12411950.
59. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002, 90:1064-1071. 10.1161/01.RES.0000018941.10726.FA, 12039795.
60. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010, 5:e8852. 10.1371/journal.pone.0008852, 2810335, 20111605.
61. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008, 172:1112-1126. 10.2353/ajpath.2008.070513, 2276432, 18321997.
62. Bresnihan B, Youssef P. Macrophages in rheumatoid arthritis. The Macrophage 2002, 231-433. Oxford: Oxford University Press, Burke B, Lewis CE, 2.